Considerações sobre o uso de enoxaparina genérica em síndrome coronariana aguda

Analysis of potential drug interactions in medical clinic sector in a Hospital of João Pessoa - PB

“…According to this study, women were deemed stronger for biological reasons and also due to the fact that men are more exposed to violence and require longer hospitalization for recovery, thereby making them more susceptible to drug interactions. Studies like Gomes et al (2010) and Yunes, Coelho, Almeida (2011) show that several interactions can occur in drugs prescribed in hospitals, corroborating results obtained in the present study. According to Micromedex® database, we found 301 interactions among the 94 medicines prescribed for This classification divides drugs into groups and subgroups (levels) according to target organ or system as well as its chemical, pharmacological, and therapeutic properties.…”

Generic Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery

“…Finally, this study limited its evaluation to VTE prophylaxis in major abdominal surgery, and further extrapolation of the indications for these compounds, such as in acute coronary syndromes should be addressed with caution. 22 Conversely, if further studies demonstrate that those compounds are effective and safe as the branded drugs in different indications, with acceptable biochemical profiles, with low costs, with an acceptable immunogenic profile, it would be a viable option for a large group of hospitals and patients that cannot afford branded LMWH. There is only 1 generic version of enoxaparin commercially available in the United States, produced by Sandoz/ Momenta.…”

Debate propositivo sobre os biossimilares de enoxaparina no Brasil

“…In Brazil, that debate has been limited to a few public discussions and recent publications 1,2 . The international debate, however, has been much more challenging.…”

“…The two articles recently published 1,2 in this journal have only provided information about the requirements for clinical trials with those drugs, but they have not provided data to answer the essential question of similarity between them. In fact, they are opinion articles.…”